Apimeds Pharma jumps as FDA backs faster approval path for non-opioid pain drugs

** Shares of drug developer Apimeds Pharmaceuticals APUS.A rise 2.4% to $1.99

** Late on Thursday, co welcomed new FDA draft guidance on non-opioid pain therapies

** Co said the U.S. FDA's proposal could help move its lead non-opioid drug candidate, Apitox, more quickly through clinical trials and toward regulatory approval

** Apitox is being developed to treat chronic pain caused by osteoarthritis, a condition that leads to long-term joint damage and reduced mobility

** As of last close, stock down 11.8% YTD